C07K 2317/33
Crossreactivity
Official title: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K2317/33 (Crossreactivity) appears on 4,332 US grants and 8,179 published applications in this corpus.
Search patents in C07K- Granted patents
- 4,332
- Published applications
- 8,179
- Assignees
- 2,185
- Inventors
- 13,873
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 4 |
| 2003 | 1 | 8 |
| 2004 | 2 | 7 |
| 2005 | 1 | 16 |
| 2006 | 2 | 12 |
| 2007 | 5 | 18 |
| 2008 | 10 | 22 |
| 2009 | 17 | 50 |
| 2010 | 21 | 62 |
| 2011 | 30 | 96 |
| 2012 | 46 | 147 |
| 2013 | 74 | 217 |
| 2014 | 109 | 298 |
| 2015 | 173 | 303 |
| 2016 | 231 | 454 |
| 2017 | 271 | 464 |
| 2018 | 316 | 497 |
| 2019 | 349 | 583 |
| 2020 | 411 | 624 |
| 2021 | 387 | 681 |
| 2022 | 394 | 715 |
| 2023 | 331 | 731 |
| 2024 | 428 | 870 |
| 2025 | 455 | 773 |
| 2026 | 265 | 527 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Aggrecan binding immunoglobulins6 Oct 2026US 12,753,224 B2Ablynx N. V.
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Canine PD-L1 antibody, antigen binding fragments thereof, and methods of use thereof6 Oct 2026US 12,753,234 B2Purdue Research Foundation
- Antibody recognizing extracellular region of ALK2/ACVR16 Oct 2026US 12,753,237 B2Saitama Medical University
- Il12rb2 binding molecules and methods of use8 Oct 2026US 2026/0308265 A1Synthekine, Inc.
- Antibody that binds to c3bbb8 Oct 2026US 2026/0308278 A1Hoffmann-La Roche Inc.
- Anti-nme antibody and method of treating cancer or cancer metastasis8 Oct 2026US 2026/0308282 A1Minerva Biotechnologies Corporation
- Lentiviral delivery of anti-cd20 chimeric antigen receptors8 Oct 2026US 2026/0308622 A1
- Anti-il-13 long-acting nanobody sequence and applications thereof1 Oct 2026US 2026/0297175 A1Shanghai Novamab Biopharmaceuticals Co., Ltd.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Anti-PD1 antibodies and their use as therapeutics and diagnostics285US 8,735,553 B1BeiGene, Ltd. · 2014
- Monoclonal antibodies to programmed death 1 (PD-1)233US 8,779,105 B2Medarex, Inc. · 2014
- Targeted binding agents against B7-H1190US 8,779,108 B2MedImmune, LLC · 2014
- Methods for treating cancer using anti-PD-1 antibodies157US 9,084,776 B2E. R. Squibb & Sons, Inc. · 2015